The epithelial cell transforming gene 2 (ECT2) protooncogene encodes a Rho exchange factor, and regulates cytokinesis. ECT2 is phosphorylated in G2/M phases, but its role in the biological function is not known. Here we show that two mitotic kinases, Cdk1 and polo-like kinase 1 (Plk1), phosphorylate ECT2 in vitro. We identified an in vitro Cdk1 phosphorylation site (T412) in ECT2, which comprises a consensus phosphospecific-binding module for the Plk1 polo-box domain (PBD). Endogenous ECT2 in mitotic cells strongly associated with Plk1 PBD, and this binding was inhibited by phosphatase treatment. A phosphorylation-deficient mutant form of ECT2, T412A, did not exhibit strong association with Plk1 PBD compared with wild-type (WT) ECT2. Moreover, ECT2 T412A, but not phosphomimic T412D, displayed a diminished accumulation of GTP-bound RhoA compared with WT ECT2, suggesting that phosphorylation of Thr-412 is critical for the catalytic activity of ECT2. Moreover, while overexpression of WT ECT2 or the T412D mutant caused cortical hyperactivity in U2OS cells during cell division, this activity was not observed in cells expressing ECT2 T412A. These results suggest that ECT2 is regulated by Cdk1 and Plk1 in concert.
Introduction
Epithelial cell transforming gene 2 (ECT2) was originally isolated from epithelial cells as a transforming cDNA (Miki et al., 1991 (Miki et al., , 1993 . The carboxy-terminal (C-terminal) half of ECT2 contains a tandem array of the Dbl-homology (DH) and pleckstrin-homology (PH) domains, which catalyse guanine nucleotide exchange on Rho GTPases (Tatsumoto et al., 1999; Saito et al., 2004) . The amino-terminal (N-terminal) half of ECT2 contains the tandem BRCA1-C terminal (BRCT) repeats, which associate with proteins involved in DNA repair and cell cycle checkpoint response (Bork et al., 1997; Callebaut and Mornon, 1997) . ECT2 is localized in the nucleus of interphase cells. Removal of the central S domain that contains the nuclear localization signals stimulates the transforming activity of ECT2 (Saito et al., 2004) . The N-terminal domain of ECT2 associates with the C-terminal domain, and deletion of the N-terminal half of ECT2 abolishes autoregulation and further stimulates its transforming activity (Saito et al., 2004) . ECT2 localizes at mitotic spindles in metaphase and the midbody during cytokinesis. Expression of dominant-negative ECT2 or microinjection of anti-ECT2 antibody inhibits cytokinesis, and results in the generation of multinucleated cells (Tatsumoto et al., 1999) . ECT2 plays a critical role in the accumulation of active RhoA during cytokinesis (Kimura et al., 2000) . Furthermore, ECT2 is phosphorylated in G2/M phase and its exchange activity is regulated by phosphorylation (Tatsumoto et al., 1999 ). ECT2 appears to have an additional function in epithelial cells, since it associates with the polarity protein complex Par6/Par3/atypical protein kinase C .
Mitotic kinases, such as Cdk1, polo-like kinase 1 (Plk1), Aurora-A, and Aurora-B, are known to play a critical role in mitotic events including centrosome separation, chromosome condensation, nuclear envelope breakdown, and microtubule reorganization (Nigg et al., 1996; Nigg, 1998 Nigg, , 2001 Severson et al., 2000; Hirota et al., 2003) . The serine/threonine protein kinase Plk1 contributes to normal mitotic phase progression, and localizes at mitotic spindles in metaphase and then at the midbody in cytokinesis (Nigg et al., 1996; Yuan et al., 2002) . The polo-box domain (PBD) of Plk1 can function as a dominant-negative mutant, and induces pre-anaphase arrest and cytokinesis failure (Seong et al., 2002) . Plk1 PBD serves as a specific phospho-Ser-or phospho-Thr-binding domain, which recognizes a subset of substrates phosphorylated by proline-directed protein kinases (Elia et al., 2003a) . A known Plk1 substrate, Cdc25, is first phosphorylated by Cdk1, and this phosphorylation provides a binding site for Plk1. Bound Plk1 then phosphorylates Cdc25 at distinct sites. His-538 and Lys-540 in Plk1 are the residues within the PBD pincer grip, and make contact with the phosphate group. Consistent with these observations, mutations at His-538 and Lys-540 in Plk1 abolish the association with Cdc25 in vivo (Elia et al., 2003b) . Whereas expression of Plk1 PBD induces an increase in the population of cells in G2/M phase, the mutations at His-538 and Lys-540 efficiently abolish this phenotype (Elia et al., 2003b) , suggesting that the phospholigand-binding activity of Plk1 PBD is necessary for proper mitotic progression. Although the phosphospecific association of Plk1 is well documented concerning Cdc25, it is still not known whether other Plk1 substrates require priming phosphorylation by Cdk1.
In this study, we show that ECT2 is phosphorylated by Cdk1 and Plk1 in vitro. ECT2 contains an in vitro Cdk1 phosphorylation site, which potentially interacts with Plk1 in a phosphospecific manner in M phase. Moreover, the phosphorylation-deficient mutant of the binding sequence diminishes ECT2-induced RhoA activation and cortical hyperactivity. These results suggest that Plk1 binding to the Cdk1-primed ECT2 is critical to the function of ECT2.
Results

ECT2 is phosphorylated by Cdk1 and Plk1 in vitro
To examine whether ECT2 is phosphorylated by mitotic kinases, we utilized recombinant proteins containing domains of human ECT2 as substrates in an in vitro kinase assay. The N-terminal (amino acids 1-421) and C-terminal (amino acids 753-882) domains of ECT2 ( Figure 1a) were efficiently phosphorylated by p34 Cdk1 / cyclin B, while the DH domain (amino acids 414-639) was not (Figure 1 ). We found that the C domain of human ECT2 contains a consensus Cdk1 phosphorylation motif (Nigg, 1998) in the sequence Thr-Pro-LysArg (TPKR) starting at amino acid 814, which is conserved in mouse and Xenopus ECT2. A single mutation of Thr-814 to Ala greatly diminished the ability of p34 Cdk1 /cyclin B to phosphorylate recombinant ECT2-C protein (Figure 1b, left panel) . These data suggest that Thr-814 is a major Cdk1 phosphorylation site in ECT2-C in vitro. ECT2-N was also efficiently phosphorylated by Cdk1 in vitro, suggesting that additional Cdk1 phosphorylation sites exist in the ECT2-N terminal domain.
Previously, we found that ECT2 localizes to the midbody in dividing cells (Tatsumoto et al., 1999) . Another mitotic kinase, Plk1, also localizes to the midbody and plays an important role in mitosis and cytokinesis (Seong et al., 2002 ). Thus, we tested whether ECT2 is a substrate of Plk1. As shown in Figure 1b on the right, ECT2-N and ECT2-C were efficiently phosphorylated by wild-type (WT) Plk1 in vitro, while the DH domain of ECT2 was not. In contrast, a kinasedeficient Plk1 mutant failed to phosphorylate ECT2 (data not shown). In addition, WT Plk1 phosphorylated ECT2-C T814A, a mutant for the Cdk1 phosphorylation site, indicating that the T814 is not a Plk1 phosphorylation site in vitro. We found that the T814A mutation slightly reduces the exchange activity of ECT2 on Rac1 (Supplementary Figure) , but whether ECT2 is regulated by phosphorylation at this site in vivo is currently not known.
ECT2 is phosphorylated at prometaphase and metaphase Previously, we have shown that the mobility of ECT2 in gel electrophoresis is reduced in G2/M phase and this mobility shift is caused by phosphorylation (Tatsumoto et al., 1999; Kimura et al., 2000) . To examine the timing of this ECT2 phosphorylation in more detail, HeLa cells were arrested at prometaphase by nocodazole, mitotically rounded cells were isolated, and the mobility of ECT2 was examined following release from nocodazole. As shown in Figure 2a , only a slow-migrating form of ECT2 (upper band shown by *) was detected in prometaphase-arrested cells. This slow-migrating form of ECT2 was still detected 45 min after nocodazole release, but disappeared thereafter. Instead, the fastmigrating form of ECT2 appeared at 90 min after release. Under these conditions, approximately 75% of the cells were in metaphase at 45 min after nocodazole release, whereas approximately 80% were in cytokinesis 90 min after release (Figure 2b ). These results suggest Regulation of ECT2 by mitotic kinases F Niiya et al that ECT2 is in a phosphorylated state in prometaphase, but the majority of ECT2 becomes dephosphorylated before cytokinesis, as detected by mobility shift. To test whether Cdk1-dependent phosphorylation contributes to the generation of the slow-migrating form of ECT2 in G2/M phase, we utilized the Cdkspecific inhibitor BMI-1026 (Seong et al., 2003) . BMI-1026 treatment of the cells arrested by nocodazole caused disappearance of the slow-migrating form of ECT2 within 30 min (Figure 2c ). Since BMI-1026 specifically inhibits Cdk1 in vivo among the known mitotic kinases (Seong et al., 2003) , phosphorylation by Cdk1 is likely to be responsible for the generation of the slow-migrating form of ECT2.
ECT2 interacts with Plk1 in vivo
In addition to Cdk1, another mitotic kinase Plk1 also phosphorylated ECT2 at its N-and C-terminal domains (Figure 1b) . Since Plk1 exhibits subcellular localization similar to ECT2 (Nigg et al., 1996; Yuan et al., 2002) , we examined whether Plk1 associates with ECT2 in vivo. We transiently expressed Myc-tagged ECT2 and Flag- Figure 2 ECT2 phosphorylation in G2/M phase is inhibited by the Cdk1 inhibitor BMI-1026. (a) Mobility shift of ECT2 in prometaphase and metaphase. HeLa cells expressing GFP-histone H2B were treated with nocodazole for 10 h. Mitotically arrested cells were collected by the shake-off procedure and released into fresh medium in a poly-D-lysine-coated 35 mm dish. At the indicated time points, cells were lysed, and proteins were separated by 7% SDS-PAGE. ECT2 was detected by immunoblotting with anti-ECT2 antibody. (b) Cell cycle progression after nocodazole release. In the samples described in (a), the number of cells in each stage of the cell cycle was counted and expressed as a percentage of the total cell population. The stage of the cell cycle was determined by chromosomal separation, as detected by GFP-histone H2B fluorescence (nX100). (c) BMI-1026 induces ECT2 dephosphorylation. HeLa cells were arrested in prometaphase with 40 ng/ml nocodazole for 10 h, treated with vehicle alone (DMSO) or BMI-1026, and then harvested at the indicated time points. Lysates were prepared and subjected to immunoblotting analysis with anti-ECT2 antibody. To confirm the interaction of ECT2 with Plk1, we also examined whether endogenous ECT2 is coimmunoprecipitated with Flag-Plk1. When Flag-Plk1 was immunoprecipitated with anti-Flag antibody, endogenous ECT2 was detected by anti-ECT2 antibody (Figure 3b, upper) . Conversely, when endogenous ECT2 was immunoprecipitated with anti-ECT2 antibody, Flag-Plk1 was detected by anti-Flag antibody (Figure 3b , lower). These results further support that ECT2 interacts with Plk1 in vivo.
Plk1 PBD interacts preferentially with phosphorylated ECT2 in vitro Since the PBD of Plk1 recognizes its substrates, we next tested whether Plk1 PBD associates with ECT2, using GST pulldown assays. As shown in Figure 4a , GSTPlk1 PBD efficiently co-precipitated endogenous ECT2 from M-phase extracts, but only marginally from interphase lysates. GST alone did not co-precipitate any detectable amount of ECT2 from either M-phase or interphase cell lysates. These results suggest that ECT2 interacts with Plk1 PBD, and that mitotic ECT2 (phosphorylated, slow-migrating) has a stronger affinity than interphase ECT2 (nonphosphorylated, fast-migrating).
To test whether interaction of GST-Plk1 PBD with ECT2 in vitro occurs in a phosphospecific manner, we next treated the lysates with phosphatase (PPase) before pulldown assays. When M-phase cell lysates were treated with l phosphatase (lPPase), the interaction of Plk1 PBD with ECT2 was dramatically diminished (Figure 4b ). When lysates were treated with lPPase in the presence of the PPase inhibitor, ECT2 was efficiently precipitated by Plk1 PBD beads. These results demonstrate that Plk1 PBD preferentially binds to mitotic ECT2 and phosphorylation of ECT2 potently stimulates the association.
Phosphorylation of ECT2 at T412 stimulates Plk1 PBD binding It has been shown that Plk1 PBD can function as a binding domain specific to phosphopeptides with the consensus sequence of Ser-(pSer/pThr)-Pro (Elia et al., 2003a) . To examine whether ECT2 is phosphorylated at Thr-Pro (TP) and/or Ser-Pro (SP) sequences in vivo, we immunoprecipitated endogenous ECT2 from interphase and mitotic cell extracts and subjected the immunoprecipitates to immunoblotting by two phosphospecific antibodies. The anti-pTP antibody was raised against the Cdk1 phosphorylation site in p21, and recognizes phospho-TP (pTP) (Thiel et al., 2002) , whereas the anti-MPM2 antibody was raised against mitotic centrosomes, and recognizes both pTP and pSP motifs (Davis et al., 1983) . ECT2 immunoprecipitates prepared from interphase or mitotic HeLa cell lysates were subjected to immunoblotting analyses with these antibodies (Figure 5a ). Either anti-TP or anti-MPM2 antibody specifically detected the slow-migrating form of ECT2 in mitotic cell lysates, but not the fast-migrating form in interphase cell lysates ( Figure 5a ). Detection of mitotic ECT2 by anti-MPM2 antibody indicates that ECT2 is one of the MPM2 antigens which are specifically phosphorylated in mitotic cells.
Close inspection of the ECT2 sequence revealed a consensus sequence motif, Ser-Thr-Pro (STP), at amino acids 411-413 in the S domain, which functions at a hinge between the catalytic and regulatory domains (Saito et al., 2004; see Figure 1a ). To examine whether T412 is phosphorylated in vivo, we mutated this residue to Ala, and expressed it as a myc-tagged protein. This phospho-deficient mutant protein was also recognized by either anti-pTP or anti-MPM antibody (data not shown), suggesting that ECT2 is phosphorylated at multiple T/SP sequences. Thus, we next examined whether the electrophoretic mobility of ECT2 is affected phase HeLa cells were incubated with GST-Plk1 PBD (residues 326-603) beads, and then beads were collected by centrifugation. Samples were analysed on a 7.5% SDS-polyacrylamide gel, and ECT2 was visualized by anti-ECT2 antibody. An equal amount of GST-Plk1 PBD addition was verified by protein staining of the blot (lower panel). (b) Lysates prepared from interphase and mitotic phase HeLa cells were mock treated or treated with lPPase in the presence or absence of the lPPase inhibitor vanadate. GST pulldown assays were performed as in (a). WCL, whole-cell lysate.
Regulation of ECT2 by mitotic kinases F Niiya et al by a phospho-deficient mutation at T412. We transfected Myc-tagged WT or mutant ECT2 into HeLa cells, and arrested the cells at prometaphase by nocodazole treatment. Lysates were prepared from nocodazolearrested cells without further purification of mitotic cells to observe both the slow-and fast-moving bands in the same lane of the gel. When the electrophoretic mobility of the mutant protein was compared with that of WT, the mobility of the slow-migrating mitotic form of Myc-ECT2 T412A was reproducibly faster than that of WT, whereas the mobility of the fast-migrating form was similar between ECT2 WT and ECT2 T412A (Figure 5b ), indicating that phosphorylation is reduced in T412A mutant ECT2. Therefore, Thr-412 might be phosphorylated in vivo during mitosis and this phosphorylation might partially affect the mobility of ECT2 in M phase. However, ECT2 appears to be phosphorylated at multiple sites besides Thr-412, since ECT2 T412A still exhibited a mobility shift in M phase, albeit to a lesser extent. To examine whether Cdk1 is responsible for phosphorylation of ECT2 at Thr-412, the T412A mutation was introduced into the maltose-binding protein (MBP)-fused ECT2 N-terminal half (ECT2-N). In vitro kinase assays revealed that phosphorylation of the T412A mutant was significantly diminished as compared with the WT protein (Figure 5c ), suggesting that Thr-412 is a major Cdk1 phosphorylation site in ECT2-N in vitro. Additionally, another potential Cdk1 phosphorylation site mutant, MBP-ECT2-N T327A, was phosphorylated at a level similar to the WT protein.
To test whether phosphorylation of ECT2 at Thr-412 is critical for Plk1 binding, we expressed Myc-ECT2 fusion proteins in HeLa cells, synchronized to M phase, and pulled down ECT2 using GST-Plk1 PBD fusion protein beads (Figure 5d ). Myc-tagged WT ECT2 was efficiently pulled down by GST-Plk1 PBD, but not by GST alone. Interestingly, the substitution of Ala for Thr-412 significantly reduced the ability of Myc-ECT2 to interact with Plk1 PBD in mitotic HeLa cells. In contrast, the phosphomimic mutation T412D did not reduce the Plk1 PBD binding (data not shown). The expression levels of WT and mutant ECT2 were comparable. These results suggest that phosphorylation of ECT2 at Thr-412 increases Plk1 PBD binding in vitro.
RhoA activation is diminished by the T412A mutation To investigate whether the phosphorylation of ECT2 at Thr-412 affects RhoA activation, we performed pulldown assays using the GST-tagged Rho-binding domain Regulation of ECT2 by mitotic kinases F Niiya et al of Rhotekin (GST-RBD). As shown in Figure 6a , expression of ECT2 WT induced the accumulation of GTP-bound RhoA as previously reported (Saito et al., 2004) , and its efficiency was comparable to that of EGF stimulation. In contrast, expression of phosphorylationdeficient ECT2 T412A did not efficiently stimulate GTP-Rho accumulation. However, phosphomimic ECT2 T412D exhibited significant activation of RhoA, although its activity was lower than WT ECT2. These results suggest that phosphorylation of ECT2 at Thr-412 stimulates Rho activation by ECT2 in vivo.
RhoA stimulates the transcriptional activity regulated by the serum response factor (SRF) (Hill et al., 1995) , and ECT2 induces the transcriptional activity of SRF through the activation of Rho GTPases (Saito et al., 2004) . Thus, we also examined whether ECT2 T412A affects the SRF-regulated transcription using the serum responsive element (SRE)-luciferase plasmid as a reporter (Figure 6b ). Upon cotransfection of the reporter plasmid with ECT2 WT expression vector, a stimulation of the luciferase activity was observed. In contrast, induction of the activity by ECT2 T412A was only marginal. The phosphomimic ECT2 T412D efficiently induced luciferase activity, although not to the same extent as ECT2 WT. These results suggest that phosphorylation of ECT2 at Thr-412 is important for activation of SRE-regulated transcription by ECT2. Taken together, mitotic phosphorylation of ECT2 at Thr412, most likely by Cdk1, appears to play a regulatory role in activation of ECT2, possibly through Plk1 binding and subsequent phosphorylation of ECT2.
Thr-412 phosphorylation is required for cortical hyperactivity during cell division During the course of the study, we found that the transfection efficiency of GFP-ECT2 WT was very low when compared with GFP alone (Figure 7a ). This phenotype hampered experiments to test whether mutations in ECT2 affect its biological function, regulation of cytokinesis. Close examination revealed that the transfection efficiency of these expression vectors was not significantly different at an early stage of transfection (24 h after transfection) as detected by GFP fluorescence. However, the number of cells expressing GFP-ECT2 WT dramatically decreased thereafter, whereas the number of cells expressing GFP alone remained at the same level (Figure 7b) . Therefore, overexpression of GFP-ECT2 WT appeared to be toxic to the cells, and thus transfectants might be eliminated from the population. Interestingly, introduction of the T412A mutation abolished this phenotype. The number of cells expressing GFP-ECT2 T412A was at a level similar to GFP-ECT2 WT 24 h after transfection, but gradually increased 48 and 72 h after transfection (Figure 7b ). We also expressed the phosphomimic mutant T412D as a GFP-fusion protein. The number of cells expressing GFP-ECT2 T412D remarkably decreased 48 and 72 h after transfection, similar to cells expressing GFP-ECT2 WT. These results suggest that phosphorylation of ECT2 at Thr-412 is critical for this phenotype. We have previously found that the S domain, which contains the STP motif, regulates nuclear localization of ECT2 (Saito et al., 2004) . However, subcellular localization of ECT2 T412A and ECT2 T412D was very similar to ECT2 WT in every phase of the cell cycle examined (data not shown), suggesting that phosphorylation of ECT2 at Thr-412 did not play a major role in subcellular localization. HeLa cells were transfected with the Myc vector, Myc-ECT2 WT, Myc-ECT2 T412A, or Myc-ECT2 T412D. The GTP-bound form of RhoA was pulled down by GST-fused RBD of Rhotekin, and detected by anti-RhoA antibody. The amount of GST-RBD in reaction mixtures was determined by protein staining. Similar results were obtained in three independent experiments. (b) T412A mutation reduces the SRF-mediated transcriptional activity. HeLa cells were cotransfected with the indicated ECT2 expression vectors and SRE-LUC reporter plasmid. Activation of SRF-regulated transcriptional activity was estimated by the luciferase activity. TK-Renilla luciferase vector was used to cotransfect the cells together with the reporter plasmid for an internal control to normalize the transfection/expression efficiency.
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Rho GTPases regulate various cortical activities through actin remodeling (Hall, 1998) . Thus, we next examined the morphology of the transfectants using time-lapse microscopy. When GFP-ECT2 WT was expressed, a striking morphology was observed during cell division, and this phenotype was evident in U2OS cells. After nuclear membrane breakdown, these cells began to exhibit hyper cortical activity. A number of processes and blebs were induced upon rounding up (Figure 8, 30 min) , and larger processes and blebs became evident in later stages (Figure 8, arrows) . Some cells collapsed in the stage of cytokinesis, whereas others exhibited incomplete cytokinesis after excessive blebbing. Cells expressing GFP-ECT2 T412D also showed a similar phenotype. In contrast, cells expressing GFP-ECT2 T412A as well as GFP alone underwent normal cell cycle division and did not exhibit excessive membrane blebbing. Approximately 98% of cells expressing WT ECT2 (n ¼ 58) or ECT2 T412D (n ¼ 44) exhibited excessive membrane blebbing, whereas approximately 3% of cells expressing ECT2 T412A (n ¼ 55) showed this phenotype. These results suggest that overexpression of ECT2 induces abnormal cortical activity leading to cell death, and that phosphorylation at Thr-412 is required for this activity.
Discussion
In this report we show that ECT2 is phosphorylated at Thr-412 in G2/M phase, most likely by Cdk1, and this phosphorylation creates a phosphospecific binding site for Plk1 PBD. The T412A mutant of ECT2 exhibited a reduced accumulation of GTP-RhoA and impaired induction of cortical hyperactivity.
We demonstrate that ECT2 is a substrate of Cdk1 and Plk1 in vitro. The N-terminal half and the C-terminal domain of ECT2 were phosphorylated by Cdk1/cyclin B and Plk1 in vitro. The mobility shift of ECT2 had already occurred when cells entered prometaphase. This slow-migrating form of ECT2 disappeared before cytokinesis ( Figure 2 ). As the Cdk-specific inhibitor BMI-1026 inhibited this mobility shift and the mobility shift was observed only at G2/M phase, the slowmigrating form might be created by ECT2 phosphorylation by Cdk1. Alternatively, Cdk1 activates another mitotic kinase, which subsequently phosphorylates ECT2. Using GST pulldown assays, we showed that GST-Plk1 PBD efficiently binds to ECT2 in M-phase cell extracts. Dephosphorylation of proteins in M-phase cell lysates by the dual-specificity lPPase dramatically reduced the association of ECT2 with GST-Plk1 PBD. As GST-Plk1 PBD efficiently pulled down ECT2 from M-phase lysates treated with lPPase in the presence of vanadate, which inhibits lPPase (Reiter et al., 2002) , phosphorylation of ECT2 appears to be important for efficient association of ECT2 and Plk1 PBD. As the addition of vanadate apparently stimulated the association of ECT2 with Plk1 PBD, vanadate might prevent dephosphorylation of ECT2 from unknown PPases in the lysates. These results strongly suggest that M-phasespecific ECT2 phosphorylation stimulates the association with Plk1 PBD.
We also found that GST-Plk1 PBD weakly associates with ECT2 in interphase lysates (Figure 4a ). However, this association of ECT2 and Plk1 PBD in interphase cells may not be phosphospecific, since treatment with lPPase did not affect the association (data not shown). Thus, the association of Plk1 PBD with ECT2 may not require phosphorylation, but phosphorylation dramatically stimulates the association. These binding characteristics of Cdk1-phosphorylated ECT2 and Plk1 PBD are similar to those of Cdk1-phosphorylated CDC25 and Plk1 PBD (Elia et al., 2003a) .
We identified the consensus-binding motif of Plk1 around Thr-412. As the phospho-deficient ECT2-N T412A mutant protein was barely phosphorylated by 
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Cdk1/cyclin B in vitro when compared with ECT2-N WT, Thr-412 appears to be a major Cdk1 phosphorylation site of ECT2-N in vitro. We also found that the association of Plk1 PBD with ECT2 T412A is very weak when compared with WT ECT2 (Figure 5d ). Therefore, phosphorylation of ECT2 at Thr-412 appears to be important for the association with Plk1. However, it seems likely that nonphosphorylated ECT2 still can associate with Plk1, as ECT2 T412A bound to Plk1 albeit weakly. This is consistent with weak association of interphase ECT2 with Plk1 (Figure 4) . It is also possible that Plk1 can phosphorylate ECT2 without Figure 8 T412A mutation abolishes cortical hyperactivity induced by ECT2 overexpression. U2OS cells were transfected with GFP-fused ECT2 WT, ECT2 T412A, or ECT2 T412D expression vector, and their morphologies were recorded by time-lapse microscopy during the whole process of cell division. Blebs and processes observed at 45 min after cell rounding are shown by arrows.
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F Niiya et al 'priming' (phosphorylation at T412), as most of the known substrates of Plk1 lack the consensus priming site. The role of phosphorylation of ECT2 by Plk1 might be to stimulate ECT2 at a spatio-temporal manner. Plk1 localizes to the centrosomes at metaphase, to the spindle midzone in anaphase, and to the midbody during cytokinesis (Seong et al., 2002) . ECT2 is also localized at the spindle midzone and midbody in HeLa cells, where Plk1 might interact with ECT2. Since Plk1 is known to regulate cytokinesis as well as other mitotic functions (Song and Lee, 2001; Seong et al., 2002) , it is possible that Plk1 regulates cytokinesis through phosphorylation of ECT2. Further studies on identification of the sites phosphorylated by Plk1 and mutational analyses of these sites should clarify the physiological role of ECT2 phosphorylation by Plk1 for cytokinesis. Previously, we found that overexpression of ECT2 increases its cytoplasmic localization, resulting in Rho activation (Saito et al., 2004) . Using this system, we showed that, while WT ECT2 efficiently induces the accumulation of GTP-bound RhoA in HeLa cells, the phosphorylation-deficient mutant T412A does not (Figure 6a ). In contrast, the phosphomimic mutant T412D did induce the accumulation of RhoA. Moreover, WT ECT2 and the T412D mutant stimulated SRFregulated transcriptional activity, which is controlled by actin polymerization through Rho GTPases (Hill et al., 1995; Miralles et al., 2003) , whereas the activity of the T412A mutant was significantly reduced. While the T to A substitution is believed to be structurally conservative, one might think that the loss of function of ECT2 T412A was due to the generation of a nonfunctional form as a result of a drastic structural change rather than an inability to be phosphorylated. However, the structure of ECT2 T412A may not be drastically altered by the mutation by following reasons. First, ECT2 T412A still exhibited nuclear localization in interphase (Figure 7a) . Second, ECT2 T412A retained a residual activity as determined by the accumulation of GTP-bound Rho (Figure 6a ) and SRF-mediated transcription (Figure 6b) . Therefore, phosphorylation of ECT2 at Thr-412 might play an important role in the catalytic activity of ECT2. Previously, we have reported that phosphorylation of ECT2 is required for its exchange activity (Tatsumoto et al., 1999) . Thr-412 appears to be one of such phosphorylation sites required for the exchange activity of ECT2. As phosphorylation of this site stimulated Plk1 PBD binding in vitro and both ECT2 and Plk1 were similarly localized at the mitotic spindles and midbody, Plk1 may further phosphorylate ECT2 at an unidentified site after binding to ECT2. Identification of Plk1 phosphorylation sites in ECT2 is under investigation.
As we did not observe the slow-migrating form of ECT2 during cytokinesis (Figure 2a ), ECT2 appears not phosphorylated at this stage. However, it is possible that phosphorylation of ECT2 at some sites does not affect the electrophoretic mobility. ECT2 appears to be still in a phosphorylated state during cytokinesis, as detected by metabolic labeling (unpublished results). Thus, some phosphorylated forms during cytokinesis might not be detectable as a slow-migrating band. Since Cdk1 is not active in this stage, this phosphorylation might have been catalysed by other kinases such as Plk1. As discussed above, phosphorylation of ECT2 presumably by Cdk1 might stimulate Plk1-binding to ECT2, and then Plk1 might phosphorylate ECT2. This phosphorylation may be maintained even after Cdk1 phosphorylation sites are dephosphorylated. It is tempting to speculate that such a relay mechanism keeps ECT2 active to regulate cytokinesis even after dephosphorylation of Cdk1 phosphorylation sites.
To investigate the mutant phenotype of T412A, we attempted to knock down ECT2 and express siRNAresistant mutant proteins. However, we could not utilize this strategy, as we found that the number of cells with GFP fluorescence was very low when ECT2 WT or the T412D mutant was expressed as GFP-fusion proteins. Interestingly, the T412A mutant or GFP alone did not show this phenotype. Subsequently, we found that the transfection efficiency of these expression vectors was comparable, but cells expressing WT or T412D ECT2 were removed from the population at an early stage after transfection. Examination of cell morphology by timelapse fluorescence microscopy revealed excessive membrane blebbing in these cells during cytokinesis (Figure 8) . As blebbing is observed around the cleavage furrow during normal cytokinesis (Wong et al., 2000) , the excessive blebbing observed in ECT2 WT-or T412D-expressing cells may be due to cortical hyperactivity induced by overexpression of ECT2. It has been reported that RhoA is activated during cytokinesis (Kimura et al., 2000; Yoshizaki et al., 2003) . Since RhoA is required for cortical retraction and rigidity during cell rounding (Maddox and Burridge, 2003) , cortical hyperactivity during cell division induced by ECT2 WT overexpression may be attributed to RhoA activation. Further, this phenotype was similar to that induced by overexpression of constitutive active RhoA (Lee et al., 2004) . In contrast to ECT2 WT and T412D, T412A did not induce excessive blebbing. This is consistent with the result that ECT2 T412A exhibited reduced accumulation of GTPRho and SRF-regulated transcriptional activity when compared with WT ECT2. How is the cortical activity related to cytokinesis? When cultured cells divide, two daughter cells look for available space upon spreading. To change their locations, the daughter cells become polarized, with numerous protrusions in the direction of motion, and a more rounded profile observed on the trailing side. Additionally, as the contraction of the cleavage furrow proceeds, new membrane particles must be inserted in the vicinity of the furrow to adjust the cortical tension. Therefore, cortical cytoskeletal rearrangements might be necessary during cytokinesis. Cortical hyperactivity induced by overexpression of ECT2 may be attributed to such functions.
Materials and methods
Protein expression N-terminal (amino acids 1-421), DH (amino acids 414-639), and C-terminal (amino acids 753-882) domains of human Regulation of ECT2 by mitotic kinases F Niiya et al ECT2 proteins were expressed in Escherichia coli as thioredoxin and oligohistidine fusion proteins using the pET-32 vector (Novagen, Madison, WI, USA). The N-terminal domains of WT and mutant ECT2 were expressed in E. coli as MBP fusion proteins using the pCEV-MAL vector.
In vitro kinase assays For the Cdk1 kinase assay, 2 mg of ECT2 protein was incubated with 1 U of recombinant human p34 cdk1 /cyclin B (New England Biolabs, Beverly, MA, USA) and 5 mCi of [g-32 P]ATP at 301C for 15 min in 20 ml. Histone H1 (1 mg) (Roche, Indianapolis, IN, USA) was used as a positive control for Cdk1 kinase. For the Plk1 kinase assay, 2 mg of ECT2 protein was incubated with 1 mg of Plk1 kinase purified from baculovirus-infected Sf9 cells, and 10 mCi of [g-32 P]ATP at 301C for 30 min in 20 ml. Casein, 4 mg was used as a positive control for Plk1 kinase. Reactions were terminated by adding an equal volume of 2 Â sample buffer. The samples were separated by 8% SDS-PAGE, stained with Coomassie blue, and then dried prior to autoradiography.
Cell culture and synchronization HeLa cells (American Type Culture Collection, Manasas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS. U2OS cells were cultured in McCoy's medium. Cell cycle synchronization was performed by double thymidine block (Tatsumoto et al., 1999) . In brief, HeLa cells were cultured with 10 mM thymidine (Sigma, St Louis, MO, USA) for 14 h, and incubated in fresh medium for 8 h, and cultured again with thymidine-containing medium for 14 h, then synchronized interphase cells were collected. Arrested cells were either released into fresh medium to follow cell cycle progression or into the medium containing 40 ng/ml of nocodazole (Sigma) to collect the mitotic cells by mechanical shake-off. In transfection experiments, the medium was changed to serum-free Opti-MEM (Invitrogen, Carlsbad, CA, USA) before the second thymidine block. Cells were then transfected with expression vectors using FuGene6 (Roche), and subjected to immunoprecipitation or GST pulldown assays.
Immunoprecipitation and immunoblotting
HeLa cells were washed once with cold phosphate-buffered saline (PBS), and then lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 1 mM EDTA, protease inhibitor). Lysates were centrifuged at 14 000 r.p.m. for 15 min at 41C, and supernatants were collected. Identical amounts of protein from each sample were incubated with anti-Flag monoclonal antibody (Sigma), anti-Myc monoclonal antibody (Santa Cruz Biotech, Santa Cruz, CA, USA), or anti-ECT2 polyclonal antibody (Tatsumoto et al., 1999) in the lysis buffer for 2 h at 41C. Protein G-Sepharose beads were added to the mixture and it was incubated for an additional 2 h. The beads were washed three times with lysis buffer, and bound proteins were eluted from the beads in SDS sample buffer. Proteins were separated by SDS-PAGE and transferred to a PVDF membrane (Invitrogen). The membranes were blocked in 5% non-fat dry milk/PBS for 30 min at room temperature, and incubated with the primary antibodies for 1-3 h at room temperature. Bound antibodies were detected using HRPconjugated secondary antibody, followed by the ECL System (Amersham, Piscataway, NJ, USA).
DNA constructs pCEV32F3-ECT-F and pEGFP-ECT2-F were previously described (Tatsumoto et al., 1999) . The full-length fragment was digested with BamHI and EcoRI, and cloned into pcDNA3.1-Myc (Invitrogen) to express ECT2 as a Myc epitope-fused protein. Flag-tagged WT Plk1 and pGEX-4T-1-Plk1 (residues 326-603) have been described (Seong et al., 2002) . ECT2 mutants (ECT2-F T412A, ECT2-F-T412D) were prepared with the Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The following sets of specific mutant primers were used: ECT2-F-T412A (5 0 -TTCTAAAAGCTCC GCTCCAGTTCCTTC-3 0 , 5 0 -GAAGGAACTGGAGCGGA GCTTTTAGAA-3) and ECT2-F-T412D (5 0 -TTCTAAAAG CTCCGATCCAGTTCCTTC3 0 , 5 0 -GAAAAGACTGGATC GGAGCTTTTAGAA-3 0 ).
GST-Plk1 PBD pulldown assays HeLa cells in interphase or mitotic phase were washed with cold TBS, and lysed in lysis buffer (25 mM Tris/HCl, pH 7.5, 125 mM NaCl, 0.5% Nonidet P-40, 5 mM EDTA, 2 mM DTT, 4 mg/ml pepstatin, 4 mg/ml aprotinin, 4 mg/ml leupeptin). Lysates (150 mg protein) were incubated with 10 ml of glutathione beads containing 2-5 mg of GST-Plk1 PBD for 1 h at 41C. Beads were washed three times with lysis buffer. Bound proteins were eluted in sample buffer, and subjected to immunoblotting. For PPase treatment, samples were incubated with l-PPase (100 U/reaction) in the presence or absence of the PPase inhibitor vanadate at a final concentration of 1 mM for 30 min at 301C. The reaction was stopped by the addition of sample buffer and boiling.
Rho activation assays
HeLa cells were transfected with Myc-tagged ECT2-F-WT, ECT2-F-T412A, and ECT2-F-T412D expression vectors. Lysates were prepared 24 h after transfection, and the GTPbound forms of Rho were determined by pulldown assays using GST-Rhotekin according to the manufacturer's protocol (Cytoskeleton, CO, USA).
Transient expression reporter gene assays SRF reporter assays have been described (Saito et al., 2004) . In brief, firefly luciferase reporter and TK-Renilla luciferase control plasmids were cotransfected with the indicated Myctagged ECT2-F expression vector into HeLa cells. The total amount of DNA was adjusted with the additional vector DNA. Cells were lysed and luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the protocol included. Firefly luciferase activity was normalized by Renilla luciferase activity and expressed as a relative luciferase activity.
Immunofluorescence microscopy U2OS cells were cultured and transfected with the indicated GFP-tagged expression vectors. Cells were fixed with 4% formaldehyde solution for 24, 48, or 72 h after transfection, and permeabilized with 0.5% Triton X-100 in PBS. After washing, cells were blocked with 2% fetal bovine serum (FBS) in PBS for 30 min at room temperature, and then incubated with monoclonal anti-g-tubulin (Sigma) antibody for 1 h in PBS containing 0.1% Tween 20 and 2% FBS at room temperature. Alexa Fluor 488-labeled anti-mouse IgG antibody was used as a secondary antibody. DNA was stained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI: Sigma). Images of GFP-fused ECT2 proteins were captured using a microscope equipped with a SPOT RT digital camera (Diagnostic, MI, USA).
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Time-lapse video microscopy U2OS cells growing on 35 mm dishes were transfected with the indicated GFP-tagged ECT2 proteins. Cells were cultured in an environmental chamber on the stage of a Zeiss Axiovert S-100 microscope equipped with monitored X-Y-Z stages. Time-lapse images were captured at 3 min intervals by a Photometric digital camera controlled by Openlab software (Improvision, MA, USA).
